Shinpoong PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Shinpoong PharmaceuticalLtd's earnings have been declining at an average annual rate of -72.5%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 1.9% per year.
Key information
-72.5%
Earnings growth rate
-72.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 1.9% |
| Return on equity | -21.2% |
| Net Margin | -28.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Apr 24
Do Shin Poong Pharm.Co.Ltd's (KRX:019170) Earnings Warrant Your Attention?
Mar 07Declining Stock and Decent Financials: Is The Market Wrong About Shin Poong Pharm.Co.,Ltd. (KRX:019170)?
Feb 01
We Wouldn't Rely On Shin Poong Pharm.Co.Ltd's (KRX:019170) Statutory Earnings As A Guide
Jan 05Is Shin Poong Pharm.Co.Ltd (KRX:019170) Using Too Much Debt?
Dec 10Revenue & Expenses BreakdownBeta
How Shinpoong PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 200,229 | -57,325 | 82,007 | 42,277 |
| 30 Sep 23 | 209,412 | -39,734 | 81,611 | 39,785 |
| 30 Jun 23 | 213,655 | -41,006 | 81,636 | 42,798 |
| 31 Mar 23 | 210,905 | -35,736 | 79,666 | 35,467 |
| 31 Dec 22 | 209,288 | -35,377 | 77,944 | 30,383 |
| 30 Sep 22 | 200,204 | -29,831 | 77,248 | 24,498 |
| 30 Jun 22 | 195,215 | -22,480 | 76,478 | 17,323 |
| 31 Mar 22 | 191,015 | -18,362 | 71,141 | 19,085 |
| 31 Dec 21 | 189,237 | -11,584 | 68,319 | 17,334 |
| 30 Sep 21 | 188,859 | 343 | 62,800 | 13,422 |
| 30 Jun 21 | 188,575 | 3,320 | 60,318 | 8,473 |
| 31 Mar 21 | 193,587 | 4,736 | 60,600 | 7,289 |
| 31 Dec 20 | 197,751 | 5,003 | 60,202 | 5,622 |
| 30 Sep 20 | 196,870 | 5,644 | 62,987 | 6,585 |
| 30 Jun 20 | 196,803 | 5,472 | 60,402 | 7,120 |
| 31 Mar 20 | 192,157 | 6,102 | 61,733 | 6,212 |
| 31 Dec 19 | 189,722 | 5,080 | 61,970 | 5,967 |
| 30 Sep 19 | 191,716 | 3,364 | 62,964 | 4,981 |
| 30 Jun 19 | 190,211 | 3,364 | 63,668 | 4,575 |
| 31 Mar 19 | 192,411 | 2,753 | 63,371 | 4,548 |
| 31 Dec 18 | 187,389 | 2,804 | 61,767 | 4,870 |
| 30 Sep 18 | 179,881 | -2,911 | 63,910 | 5,168 |
| 30 Jun 18 | 179,047 | -838 | 64,970 | 5,127 |
| 31 Mar 18 | 180,039 | 789 | 64,067 | 5,509 |
| 31 Dec 17 | 184,998 | 1,203 | 65,978 | 4,626 |
| 30 Sep 17 | 188,217 | -14,296 | 62,783 | 4,104 |
| 30 Jun 17 | 191,300 | -17,559 | 65,936 | 4,906 |
| 31 Mar 17 | 193,081 | -18,636 | 69,032 | 4,826 |
| 31 Dec 16 | 194,147 | -20,535 | 69,864 | 6,386 |
| 30 Sep 16 | 199,984 | 5,346 | 70,716 | 7,920 |
| 30 Jun 16 | 197,739 | 5,756 | 70,883 | 6,144 |
| 31 Mar 16 | 193,094 | 1,381 | 72,443 | 7,138 |
| 31 Dec 15 | 195,950 | 1,124 | 70,590 | 9,137 |
| 30 Sep 15 | 196,991 | -4,076 | 70,964 | 9,437 |
| 30 Jun 15 | 213,185 | 896 | 71,612 | 9,437 |
| 31 Mar 15 | 219,640 | 6,934 | 69,187 | 7,524 |
| 31 Dec 14 | 220,292 | 4,058 | 68,505 | 5,751 |
| 30 Sep 14 | 219,737 | 9,005 | 68,341 | 5,306 |
| 30 Jun 14 | 208,525 | 6,247 | 64,262 | 5,306 |
| 31 Mar 14 | 210,975 | -5,292 | 65,186 | 3,013 |
| 31 Dec 13 | 215,963 | 5,438 | 61,594 | 3,585 |
| 30 Sep 13 | 219,777 | 100 | 60,925 | 2,637 |
| 30 Jun 13 | 224,896 | 6,266 | 62,314 | 2,637 |
Quality Earnings: A019170 is currently unprofitable.
Growing Profit Margin: A019170 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A019170 is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.
Accelerating Growth: Unable to compare A019170's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A019170 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A019170 has a negative Return on Equity (-21.15%), as it is currently unprofitable.